Perioperative Durvalumab Reduced Risk of Recurrence or Death vs Neoadjuvant ... - The ASCO Post

The NIAGARA trial showed durvalumab with neoadjuvant chemotherapy improved event-free and overall survival in muscle-invasive bladder cancer patients, presented at ESMO 2024 and published in NEJM.